JPRN-jRCT2080221752已完成3 期
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 4,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator)
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Adult patients. >/= 18 years of age
- •- Non-metastatic primary invasive HER2-positive carcinoma of the breast that is adequately excised, and that is either node-positive (except T0) or node-negative but with presence of at least one risk factor as defined by the protocol
- •- Eastern Cooperative Oncology Group (ECOG) performance status - The interval between definitive surgery for breast cancer and the first dose of chemotherapy must be no more than 8 weeks (56 days). The first cycle of chemotherapy must be administered within 7 days of randomization or on Day 56, whichever occurs first.
- •- Known hormone receptor status (estrogen receptor and progesterone receptor)
- •- Baseline LVEF >/= 55%
- •- Women of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception (as defined by the protocol) by the patient and/or partner for the duration of the study treatment and for at least 6 months after the last dose of study drug
排除标准
- •- History of any prior (ipsi- and/or contralateral) invasive breast cancer
- •- History of non-breast malignancies within the 5 years prior to study entry, except for carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin
- •- Any clinical T4 tumor as defined by TNM, including inflammatory breast cancer
- •- Any previous systemic chemotherapy for cancer or radiotherapy for cancer
- •- Prior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancer
- •- Concurrent anti-cancer treatment in another investigational trial
- •- Serious cardiac or cardiovascular disease or condition
- •- Pregnant or lactating women
研究者
相似试验
招募中
不适用
Observational study of Pertuzumab in combination with Trastuzumab and Docetaxel in patients with metastatic HER2-positive breast cancer that have the history of Trastuzumab treatmentmetastatic breast cancerJPRN-UMIN000012444Osaka City University Graduate School of Medicine20
已完成
3 期
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric CancerHER2-positive metastatic gastroesophageal junction or gastric cancerJPRN-jRCT2080222112Chugai Pharmaceutical Co., Ltd.780
已完成
不适用
Effect of Additional pertuzumab for the post treatment in Patients with HER2 positive locally advanced/ metastatic Breast Cancer Who Were Previously Treated with pertuzumab - Phase II studybreast cancerJPRN-UMIN000020837Setouchi Breast Project Comprehensive Support Organization30
进行中（未招募）
1 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer - PERNETTAEUCTR2012-002556-17-FRICANCER208
已完成
2 期
A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer10006291Breast cancerNL-OMON44863ICANCER26